Who Should Not Take HRT? The Honest, Complete Answer
The HRT Index is an independent comparison resource for HRT telehealth providers. This page is educational and isn't a substitute for advice from your own clinician. · Last verified: June 15, 2026.
If you're asking who should not take HRT, here's the straight answer first: a specific group genuinely should not start systemic hormone replacement therapy without a doctor checking them first. The biggest red flags are unexplained vaginal bleeding, a history of breast cancer or another estrogen-fed cancer, blood clots, a past stroke or heart attack, active liver disease, a known clotting disorder, or a possible pregnancy.
Here's the reassuring part most pages bury, though. The list of people who truly shouldn't is shorter and more specificthan the fear makes it feel. A few of those “hard no” situations are really “not yet — get this checked first.” And the way you take HRT — a pill, a patch, or a low-dose vaginal cream — can change the answer completely.
We'll be straight with you about something else, too: no website can tell you personally whether HRT is safe for your body. Anyone who promises that is guessing. What this page does instead is show you which situations are true red flags, which ones just need a closer look, and the exact questions that get you a real answer from a real clinician — fast.
Start with the quick map below:
| Your situation | Where to start |
|---|---|
| A red-flag history (cancer, clot, stroke, liver, unexplained bleeding) | A clinician or specialist first — not a routine sign-up |
| Age 60+, or more than 10 years past menopause | An individual risk review before starting |
| Only vaginal dryness or painful sex | Ask about local options before whole-body HRT |
| Bothersome symptoms and none of the above | A prescriber, or an online menopause consult, may be reasonable |
Not sure which row is you? Our free 60-second check turns your answers into a one-page summary you can take to your doctor — and points red-flag readers to a clinician first.
Take the free HRT red-flag check →Who should not take HRT? The short answer
People with unexplained vaginal bleeding, a current or past history of breast or other estrogen-sensitive cancer, a history of blood clots, stroke, or heart attack, active liver disease, a known clotting disorder, or a possible pregnancy should not start systemic HRT (hormones that travel through your whole body) without medical evaluation first. These categories appear across current FDA labeling for common estrogen or estrogen-progestogen products,[1,2]though the exact wording varies by product and route. Some of them have specialist exceptions, but every one needs a clinician's review rather than a quick online sign-up.
A quick definition before we go further. Systemic HRT means estrogen — and usually progesterone if you still have a uterus — delivered as a pill, patch, gel, spray, or higher-dose ring, so it reaches your whole body. That's different from low-dose vaginal estrogen, which mostly stays in one area and follows different rules (more on that below). When doctors talk about who “can't” take HRT, they almost always mean the systemic kind.
Current FDA labeling for systemic menopausal estrogen products lists the same core set of “do not use” conditions. The exact list varies a little by product — the plain estradiol tablet names eight, while the patch, gel, and vaginal versions add inherited clotting disorders.[1,2] Here they are in plain English:
- Unexplained vaginal bleedingthat hasn't been checked out yet.
- Breast cancer— current, past, or suspected. (There's a narrow exception some specialists make in advanced cancer care, but as a starting point, it's a no.)
- Any other estrogen-fed (estrogen-dependent) cancer, such as certain uterine cancers.
- A past or current blood clot in a vein — deep vein thrombosis (DVT, a clot usually in the leg) or pulmonary embolism (PE, a clot in the lungs).
- A recent stroke or heart attack, or active heart artery disease.
- A severe allergic reaction (like swelling or anaphylaxis) to a hormone product.
- Active liver disease or poor liver function.
- A known inherited clotting disorder — things like Factor V Leiden or protein C, protein S, or antithrombin deficiency (genetic conditions that make your blood clot too easily). This appears on the patch, gel, and vaginal estrogen labels.
- Known or suspected pregnancy. Menopause HRT is not for pregnancy.
If one of those is you, it doesn't automatically mean you'll suffer forever. It means HRT isn't a do-it-yourself decision, and there may be a safer route or a non-hormone option. We'll cover both below.
The important nuance most pages skip
Not every scary-sounding health issue is a hard stop. A familyhistory of breast cancer is not the same as having had breast cancer yourself. Controlled high blood pressure, well-managed diabetes, migraines, being over 60, or being more than 10 years past menopause can all change the conversation — but they don't always mean “never.” They usually mean “let's pick the safest type and dose,” not “go home.”
Find your bucket: the HRT red-flag traffic light
Most contraindication lists dump every condition into one scary pile. That's not how clinicians actually think, and it's not helpful to you. We sorted the common situations into three buckets — red, yellow, and green — based on the FDA “do not use” categories, major guidelines from ACOG and the Menopause Society, and the timing data from Mayo Clinic and Cleveland Clinic.
| Your situation | Bucket | What it means | What to ask | Basis |
|---|---|---|---|---|
| Unexplained or new vaginal bleeding | 🔴 Red | Don't start until it's checked | “What test do I need first?” | FDA label |
| Current, past, or suspected breast cancer | 🔴 Red — specialist | Usually not recommended, especially hormone-receptor-positive | Specialist + your oncologist | FDA label |
| Uterine/endometrial or other estrogen-fed cancer | 🔴 Red — specialist | Not a routine online start | Clarify your exact cancer type | FDA label |
| Past blood clot (DVT/PE) or inherited clotting disorder | 🔴/🟡 Red / Yellow | Not a casual start; route and risk matter | “Do I need a clotting workup?” | FDA label + guideline |
| Past stroke, heart attack, or heart artery disease | 🔴 Red — specialist | Usually not a simple online start | Cardiology-aware menopause care | FDA label |
| Active liver disease | 🔴 Red | May be unsafe or need a different route | Treat the liver issue first | FDA label |
| Possibly pregnant | 🔴 Red | Menopause HRT is not for pregnancy | A pregnancy test and a check | FDA label |
| Starting after age 60, or 10+ years past menopause | 🟡 Yellow | Not “never,” but the risk-benefit math shifts | “Do the benefits beat the risks for me?” | Timing data |
| Family history of breast cancer (no personal history) | 🟡 Yellow | Not the same as a personal diagnosis | Your personal risk and HRT type | Guideline + evidence |
| Migraine with aura | 🟡 Yellow | A route-and-risk talk, not a DIY call | “Is a patch or non-hormone option safer?” | Guideline |
| Controlled high blood pressure or diabetes | 🟡 Yellow | Often workable once it's managed | How your numbers affect the choice | Guideline |
| Only vaginal dryness or painful sex, no other symptoms | 🟢 Green — different path | Whole-body HRT may not be needed at all | Low-dose vaginal or local options | Symptom-based |
| Bothersome menopause symptoms, none of the above | 🟢 Green | No obvious red flags — but you still need a prescriber | Online care vs in-person | Guideline |
This table is the fastest way to see where you stand. But “yellow” and “green” still come down to your personal history, and “red” still has exceptions a specialist can weigh. Each row's basis is explained in detail below, with sources. See also our full HRT contraindications guide and HRT benefits and risks overview.
Want this as a checklist you can hand to your doctor? Our free 60-second check turns your answers into a personalized one-page summary — the red flags to mention and the exact questions to ask at your appointment.
Get a personalized red-flag checklist →First, what kind of HRT are we even talking about?
“HRT” is not one thing, and the contraindications change depending on the type. The short version: systemic HRT (whole-body) follows the strictest rules, while low-dose vaginal estrogen (local) is treated more gently in clinical practice. Menopause hormone therapy also comes in estrogen-only versus combined versions. This page is about menopause hormone therapy specifically — not testosterone therapy, not gender-affirming hormones, and not fertility or cancer hormone treatments, which all follow different rules.
Systemic HRT
Systemic HRT reaches your whole body. It includes:
- Pills
- Skin patches
- Gels and sprays
- Higher-dose vaginal rings that release hormones body-wide
Local (low-dose) vaginal estrogen
Local vaginal estrogen mostly stays put. It includes vaginal creams, tablets, inserts, and low-dose rings, used mainly for vaginal dryness, painful sex, and repeat urinary symptoms — what doctors call genitourinary syndrome of menopause. Because very little hormone reaches the bloodstream, clinical guidelines often treat it differently from systemic HRT — though, as you'll see, the product labels haven't fully caught up.
Estrogen-only vs. combined
If you've had a hysterectomy (no uterus), you're typically given estrogen alone. If you still have a uterus, estrogen by itself can overgrow the uterine lining and raise the risk of uterine cancer — so clinicians add a progestogen(progesterone or a progestin) to protect it. That's why “estrogen-only when you still have a uterus” is a red flag. It's not that you can't take HRT; it's that you need the protective second hormone. Our full explainer on whether you need progesterone with a uterus covers this in detail.
Can I take HRT if I had breast cancer or it runs in my family?
A personal history of breast cancer — especially hormone-receptor-positive breast cancer — is usually a reason to avoid systemic HRT, unless a specialist-led discussion decides otherwise. A family history of breast cancer is a different category: it belongs in your risk assessment, but the evidence suggests it does not add to HRT-related breast cancer risk the way a personal diagnosis does.
If you've had breast cancer
Systemic HRT can, in theory, feed cancers that grow on hormones. So the standing recommendation is to avoid it. Major cancer centers advise against HRT for people with a history of hormone-receptor-positive breast cancer. In rare cases with severe symptoms, an oncologist and menopause specialist may weigh a limited exception together — but that's individual cancer care, not a green light, and not something to arrange through an online intake form.
If breast cancer runs in your family but you've never had it
This is where many women wrongly disqualify themselves. The data is actually reassuring. Cancer Australia's position is that family history appears to have no additive impact on breast cancer risk from HRT.[7]A large analysis from the Women's Health Initiative found that family history and combined HRT have separate, non-interacting effects — meaning HRT didn't amplify the family-history risk.[8]So “my aunt had breast cancer” is not, by itself, a medical no. It's a reason to talk through your personal risk, your mammogram history, and which type of HRT fits.
It also helps to know that not all HRT carries the same breast-cancer signal:
- Combined estrogen-progestogen HRT is linked to roughly 1.7 times the breast cancer risk of never-users among longer-term users.[7]
- Estrogen-only HRT carries a much smaller signal — some studies show little to no increase. (Remember, estrogen-only is only for women without a uterus, or paired with a progestogen.)
That difference is real, but it never overrides a personal history of breast cancer. If that's you, the route forward is a specialist conversation — and we'll point you to non-hormone options that can still bring relief.
Can I take HRT after a blood clot, stroke, or heart attack?
A history of blood clots (DVT or PE), stroke, heart attack, heart artery disease, or an inherited clotting disorder makes systemic HRT a specialist-first decision rather than a casual online start. Two things matter most here: your personal risk level, and the routeyou'd take HRT, because oral estrogen and skin-based estrogen affect clotting risk very differently.
So if you've had a clot, the questions aren't “yes or no” — they're “how high is my risk, do I need a clotting workup, and is a non-oral route or a non-hormone option safer for me?” A prior clot or clotting disorder still needs clinician or specialist review; the route matters, but it doesn't make the decision casual.
For stroke and heart disease, the same logic applies: it's a risk-stratification decision, timing matters, and if your cardiovascular risk is high, non-hormone treatments may simply be the better first step. None of this belongs in a five-minute online questionnaire.
Read more in our HRT benefits and risks guide and HRT side effects page.
What about liver disease, unexplained bleeding, pregnancy, or a hormone allergy?
These four are on the “do not use” list too, and each has a simple logic. Active liver disease, unexplained vaginal bleeding, a possible pregnancy, and a severe allergy to a hormone product are all contraindications on estrogen labeling — but only one of them (bleeding) can sometimes be cleared and revisited.
Active liver disease
Active liver disease or liver dysfunction is listed as a contraindication on estrogen labeling, because the liver is what processes estrogen.[1,2]If your liver isn't working well, that changes how the drug is handled. The practical move is to evaluate or treat the liver issue first, then revisit — and depending on the situation, a non-oral route or a non-hormone option may be considered. That's a clinician's call after they've looked at your liver function, not a self-start.
Unexplained vaginal bleeding
Unexplained vaginal bleeding is one of the clearest reasons not to start HRT until it's evaluated. The point isn't to scare you — it's to make sure bleeding isn't a sign of something that should be diagnosed before any hormones are added. Bleeding after menopause always needs a check. Heavy or irregular bleeding during perimenopause may need one too, depending on the pattern.
Importantly, this is the one situation where even low-dose vaginal estrogen— which is otherwise much gentler — still shouldn't start until the bleeding is sorted out. Get the cause checked first; hormones can wait.
Possible pregnancy and severe allergy
Menopause HRT is not for pregnancy, so a known or suspected pregnancy is a contraindication; if pregnancy is possible, that needs to be ruled out first. A severe allergic reaction — such as swelling (angioedema) or anaphylaxis — to a hormone product is also a clear reason not to use that product again. These two are the most straightforward on the list: if pregnancy is even possible, a quick test settles it; if a hormone product once caused a serious allergic reaction, that specific product is off the table.
Can I start HRT after 60 or more than 10 years after menopause?
Starting systemic HRT after age 60, or more than 10 years past menopause, is not automatically “too late” — but the benefit-to-risk balance shifts, so it calls for an individual review rather than a quick yes. The most favorable window is starting before age 60 or within 10 years of menopause, what researchers call the timing hypothesis.
This is the single most misunderstood “yellow flag,” so it's worth being precise. Mayo Clinic and Cleveland Clinic both note that starting after 60, or more than a decade past menopause, raises the odds of serious complications like clots and stroke. Tellingly, when the FDA updated HRT labels in 2025–2026, it added exactly this timing language — telling clinicians to consider starting within 10 years of menopause or before age 60 to get the best balance.[3]Starting later isn't forbidden; it just calls for the lowest effective dose, often a non-oral route, and an honest individual risk review.
If you're over 60, the useful questions are: “What are we treating — hot flashes, sleep, vaginal symptoms, or bone health? Do I need whole-body treatment, or would a patch or a local option fit better? And which of my risk factors should we weigh?”
Which HRT red flags are NOT automatic no's?
Some conditions change the HRT conversation without ruling it out. A family history of breast cancer, migraine with aura, controlled high blood pressure or diabetes, smoking, and high triglycerides are reasons to screen carefully and choose the right type and dose — not reasons to give up on HRT.
Migraine with aura
Migraine with aura (the kind with visual or sensory warning signs) is a route-and-risk discussion, not a DIY decision, because it can interact with stroke risk. The usual move is to ask whether a non-oral estrogen — patch or gel — or a non-hormone option is the safer fit for you. Don't self-select here.
Controlled high blood pressure or type 2 diabetes
Controlled high blood pressure or type 2 diabetes usually doesn't rule out HRT once the condition is managed; UK guidance (NICE) even says HRT can be considered for menopause symptoms in people with type 2 diabetes after the full picture is reviewed.[5] Uncontrolled high blood pressure is a different story and should be managed first.
Smoking and very high triglycerides
Smoking (especially over age 35) and very high triglycerides also push toward a non-oral route and a careful risk talk. The theme across all of these: they shape how you take HRT, not whether you can.
Did the FDA make HRT safe for everyone in 2025?
This is the most important myth on the entire topic. We checked this against the FDA's own announcement, because the headlines blurred it badly. See our full breakdown: what the FDA warning change really means and the HRT label changes of 2026.
What the FDA actually changed (November 2025)[3]
- It started removing the boxed warning language about cardiovascular disease, breast cancer, and probable dementia from menopausal hormone therapy products containing estrogen.
- It directed labels to add timing guidance — most favorable when started before 60 or within 10 years of menopause.
- It approved a first generic version of Premarin — the first such approval in over 30 years.
What the FDA did NOT change
- The Contraindications section is a separate part of the label from the boxed warning. The “do not use” list — breast cancer, clots, stroke, liver disease, undiagnosed bleeding, pregnancy — still stands.[1,2] Women with a personal history of breast cancer remain off-limits for systemic HRT.
- The information about cardiovascular and breast cancer riskwasn't deleted — it was moved out of the box and kept elsewhere in the labeling.
- The endometrial (uterine) cancer boxed warning stays on estrogen-only systemic products — the reminder that women with a uterus need a progestogen too.
- Other known risks — venous clots, stroke, and gallbladder disease — are still listed.
Does the type of HRT change who can take it? (Yes — here's the map)
Yes. The biggest blind spot in most contraindication lists is that they treat HRT as one product. In reality, the same condition can be a hard no for the oral pill, a “specialist-first” for the skin patch, and a different conversation for low-dose vaginal estrogen. This is the most useful thing on this page, so we built it into a single map.
A reminder on the three forms: oral (swallowed, passes through the liver first), transdermal (patch or gel, absorbed through skin, skips the liver), and low-dose vaginal (cream/tablet/ring, mostly stays local).
How to read it: Avoid = generally contraindicated. Specialist first = possible only with specialist sign-off. Lower concern= usually gentler, but still a clinician's decision.
| Condition | Oral estrogen (pill) | Transdermal (patch/gel) | Low-dose vaginal estrogen |
|---|---|---|---|
| Past blood clot (DVT/PE) | Avoid | Specialist first — lower clot risk than pills | Label lists as contraindication; specialist decision |
| Inherited clotting disorder | Avoid | Specialist first | Label lists as contraindication; specialist decision |
| Past stroke / heart attack | Avoid | Specialist first | Label lists as contraindication; specialist decision |
| Personal history of breast cancer | Avoid | Avoid | Label lists as contraindication; oncologist shared-decision only |
| Active liver disease | Avoid | Specialist first (skips liver) | Label lists as contraindication; specialist decision |
| High triglycerides | Specialist first | Lower concern (skips liver) | Lower concern |
| Migraine with aura | Specialist first | Lower concern | Lower concern |
| Controlled high blood pressure | Lower concern | Lower concern | Lower concern |
| Undiagnosed vaginal bleeding | Avoid until evaluated | Avoid until evaluated | Avoid until evaluated |
| Uterus present (needs lining protection) | OK with a progestogen | OK with a progestogen | Usually OK at low dose; confirm with clinician |
Two things to take from this map
First, the patch and gel are often the workaround.For clot risk, stroke history, liver concerns, and high triglycerides, transdermal estrogen skips the liver and carries less risk than the pill. If you assumed a clot history meant “no HRT ever,” the honest answer may be “no pills— but a patch might be on the table with the right specialist.”
Second, low-dose vaginal estrogen is the subject of a live debate. Pharmacologically, very little reaches the bloodstream. A 2025 Danish registry study of more than 34,000 women with a prior stroke found that vaginal estradiol tablets were not linked to a higher risk of a second stroke.[9] ACOG also notes that low-dose vaginal estrogen may be reasonable for some breast cancer survivors at low recurrence risk — but only as a shared decision with their oncologist.[6]The catch: until the labels are revised, they still list the systemic contraindications, so a red-flag history still needs a clinician's sign-off.
Already on HRT? Red-flag symptoms to stop and call a doctor
If you're already taking HRT, certain symptoms mean stop and call your clinician promptly — not next month. The big ones point toward a possible clot, stroke, or another serious reaction, and they're worth memorizing.
- Leg pain, swelling, warmth, or redness in one leg (a possible clot).
- Sudden shortness of breath, chest pain, or coughing up blood (a possible lung clot).
- Sudden severe headache, vision changes, slurred speech, face droop, or weakness on one side (possible stroke signs).
- Yellowing of the skin or eyes, or severe belly pain (a possible liver or gallbladder problem).
- New or unusual vaginal bleedingthat your clinician hasn't already explained.
- A new breast lump or skin change.
Some light, early bleeding can happen in the first few months of HRT or after a dose change, and that's usually a follow-up conversation rather than an emergency. But anything heavy, sudden, or persistent deserves a call. When in doubt, make the call. See our full HRT side effects guide for a complete “track it / call now / emergency” symptom breakdown.
If HRT isn't right for you, what can you take instead?
If systemic HRT is off the table, you are not out of options. Depending on your main symptom, clinicians can offer FDA-approved non-hormone medicines for hot flashes, local vaginal treatments for dryness and painful sex, and a range of prescription and lifestyle approaches. Relief without systemic hormones is genuinely possible.
| Option | Hormone? | FDA-approved for hot flashes? | Prescription? | Key safety check |
|---|---|---|---|---|
| Lynkuet (elinzanetant) | No | Yes (approved Oct 24, 2025) | Yes | Pregnancy exclusion, liver monitoring, seizure history, grapefruit/CYP3A4 interactions[11] |
| Veozah (fezolinetant) | No | Yes (approved 2023) | Yes | Liver tests before starting, monthly for 3 months, then months 6 and 9[10] |
| Low-dose paroxetine (Brisdelle) | No | Yes (the SSRI approved for menopausal hot flashes) | Yes | Drug interactions; not with certain other antidepressants |
| Other SSRIs / SNRIs | No | No — used off-label | Yes | Helpful if you also have mood symptoms |
| Gabapentin | No | No — used off-label | Yes | Drowsiness; can help night sweats and sleep |
| Clonidine | No | No — used off-label | Yes | Blood pressure effects |
| Oxybutynin | No | No — used off-label | Yes | Dry mouth; sometimes used for sweating |
| Vaginal moisturizers / lubricants | No | N/A (over the counter) | No | For dryness and comfort |
| Low-dose vaginal estrogen | Yes (local) | N/A | Yes | Gentler than systemic; see the route map above |
| Prasterone (vaginal DHEA) | Hormone (local) | N/A | Yes | For painful sex |
| Ospemifene | No (non-estrogen) | N/A | Yes | For painful sex |
A note on Veozah and Lynkuet — the newest non-hormone options come with real monitoring requirements:
- Veozah (fezolinetant) works well for many women, but in December 2024 the FDA added a boxed warning about rare but serious liver injury. It requires liver blood tests before you start, monthly for the first three months, and again at months 6 and 9.[10] Not a casual swap.
- Lynkuet (elinzanetant), approved October 24, 2025, is in the same non-hormone class. Its label calls for excluding pregnancy, monitoring liver function, screening for seizure history, and avoiding grapefruit and certain interacting medicines.[11]
A quick word on testosterone. You may see testosterone discussed for low libido in menopause. In the US, testosterone is a Schedule III controlled substanceunder the DEA, and always requires a prescription from a licensed clinician — there's no legitimate way around that.[13a]It's also not FDA-approved specifically for women, so any use is off-label and a doctor's decision.
Our non-hormonal menopause options guide breaks down each of these by symptom in detail. You don't have to white-knuckle your way through this.
Is it safe to start HRT online, or do you need a specialist?
For many women with no red flags, an online menopause clinic is a reasonable and convenient way to start HRT. But if you have a major red flag — a personal history of cancer, clots, stroke, heart disease, liver disease, or unexplained bleeding — a routine online intake usually isn't built to catch what an in-person specialist would, and a clinician who can review your records is the safer first step.
🟢 Green light — online care may be reasonable, if you:
- have bothersome menopause symptoms,
- have no unexplained bleeding,
- have no personal history of breast or uterine cancer,
- have no history of clots, stroke, or heart attack,
- have no active liver disease,
- are not possibly pregnant, and
- can share your medication list and mammogram/medical history.
🟡 Yellow light — get a careful review first (online or in person):
Age 60+, more than 10 years past menopause, family cancer history, migraine with aura, diabetes or high blood pressure, or a history that needs records pulled.
🔴 Red light — start with a specialist, not a sign-up form:
Personal history of breast or estrogen-fed cancer, unexplained bleeding, past clot/DVT/PE, stroke, heart attack, active liver disease, or a complex cancer or cardiovascular history.
If you're a green light and ready to explore your options:
The HRT Index compares online menopause clinics side by side so you can see your choices in one place. The fastest way in is our free 60-second matching quiz, which points you toward the providers that fit your situation — including insurance, self-pay, and state availability.
Three common starting points for green-light readers:
Midi Health — insurance-friendly, accepts many major plans, board-certified menopause clinicians. Good first call if you have coverage.
Check Midi Health ↗Winona — self-pay subscription model, flat monthly fee, FDA-approved and compounded routes clearly labeled.
Check Winona ↗Sesame Care — pay-per-visit with transparent pricing, no membership required. Good for a one-time consult or if you prefer to pay as you go.
Check Sesame Care ↗Disclosure: The HRT Index may earn a commission if you choose a provider through our links. That never changes our red-flag guidance — if you have a red flag, we point you to a clinician first.
What to ask before you start HRT
The best HRT decision isn't just “yes or no.” It's whether the type, route, dose, lining protection, and monitoring fit your actual health history. Walking in with the right facts and questions turns a rushed appointment into a real plan.
Facts to bring to your clinician
- Your age and the date of your last period
- Whether you still have your uterus (or had a hysterectomy)
- Any personal history of cancer
- Any family history of breast or other cancers
- Any history of clots, stroke, or heart problems
- Any liver disease
- Any unusual bleeding
- Whether you get migraines with aura
- Every medication and supplement you take
- Your most recent mammogram and any relevant screening history
- Your main symptoms and how much they bother you
Questions to ask
- “Based on my history, am I a candidate for systemic HRT?”
- “If not, is low-dose vaginal estrogen still an option for me?”
- “Should I avoid the oral pill and use a patch or gel instead?”
- “If I still have my uterus, what will protect my uterine lining?”
- “What exactly are we treating, and what should improve — by when?”
- “Which risks apply specifically to me?”
- “What symptoms should make me stop and call you?”
- “Which non-hormone options fit my other medications?”
- “How often will we reassess?”
Print it, screenshot it, or generate your personalized version with the free red-flag check. A prepared patient gets a better answer — every time.
Generate your personalized checklist →You're not the only one asking this
If you've been quietly worried that you're “not an HRT candidate,” you're in very good company. The same three worries come up again and again in menopause communities:
- “I can't take HRT — so what are my options?”
- “My doctor won't prescribe HRT. Is that even right?”
- “I was told I'm not a candidate, and now I feel stuck.”
Two honest things about those. First, “my doctor said no” is sometimes outdated caution rather than a true medical barrier — which is why a second opinion from a menopause-trained clinician is so often worth it, especially after the 2025 label changes. See our “Is HRT still dangerous?” explainer for the updated picture. Second, “I can't take systemic HRT” almost never means “nothing can help” — as the alternatives section above shows.
What we verified for this page
Because this is a health-and-safety topic, we think you deserve to see our work. Here's what we checked and where it came from.
| What we checked | Primary source | What changed since 2025 |
|---|---|---|
| The “do not use” categories — how they differ by tablet, patch, gel, and vaginal form | DailyMed product labels[1,2] | Not changed by the 2025 boxed-warning removal |
| The boxed-warning change: what was removed, what stayed, first generic Premarin, and timing language | FDA announcement[3] | New — broad boxed warning removed Nov 2025; rollout continued into 2026 |
| Contraindication and vaginal-estrogen guidance; clotting-risk and route guidance | ACOG; NICE[5,6] | Stable guidance |
| Breast cancer risk for combined vs estrogen-only HRT; the family-history evidence | Cancer Australia; WHI analyses[7,8] | Stable evidence |
| Vaginal estrogen and recurrent stroke (more than 34,000 women) | Stroke, American Heart Association[9] | New study (2025) |
| The newest non-hormone options and their FDA safety requirements | FDA Veozah safety communication; FDA/DailyMed Lynkuet label[10,11] | Veozah liver boxed warning Dec 2024; Lynkuet approved Oct 2025 |
| Testosterone status (Schedule III; not FDA-approved for women) | DEA schedules[13a] | Unchanged |
Frequently asked questions
- Who should not take HRT?
- People with unexplained vaginal bleeding, certain cancers such as breast or uterine cancer, a history of blood clots, stroke, or heart attack, a clotting disorder, active liver disease, a possible pregnancy, or a serious hormone-medicine allergy should not start systemic HRT without medical evaluation. Some of these are specialist-first situations rather than a permanent "never," and the type of HRT can change the answer.
- What are the main contraindications for HRT?
- Current FDA labeling for systemic estrogen products lists undiagnosed vaginal bleeding, known or past breast cancer, other estrogen-dependent cancer, active or past blood clots (DVT/PE), recent stroke or heart attack, severe allergic reaction to the product, and liver disease; the patch, gel, and vaginal versions also list inherited clotting disorders, and the tablet lists pregnancy. The exact wording varies by product and route, and these were not erased by the FDA's 2025 boxed-warning change.
- Can I take HRT if I had breast cancer?
- Usually not as a routine systemic-HRT start, especially with hormone-receptor-positive breast cancer, because systemic estrogen can in theory feed hormone-sensitive cancers. Severe symptoms may justify a specialist-led discussion with your oncologist, and low-dose vaginal estrogen is sometimes considered for low-recurrence-risk survivors as a shared decision — but neither is a do-it-yourself or online-intake decision.
- Can I take HRT if breast cancer runs in my family?
- Family history is not the same as a personal breast cancer diagnosis, and the evidence suggests it does not add to HRT-related breast cancer risk the way a personal history does. It should be part of an individual risk discussion that includes your personal risk factors, mammogram history, and which type of HRT you'd use — but on its own, family history is not an automatic disqualifier.
- Can I take HRT after a blood clot?
- Don't start systemic HRT casually after a DVT, PE, or with a clotting disorder; it's a specialist-first decision. Oral estrogen carries more clot risk than a skin patch or gel, which skips the liver, so the real questions are whether you need a clotting workup and whether a non-oral route or a non-hormone option is safer for you.
- Is HRT safe after 60?
- Starting systemic HRT after 60 or more than 10 years past menopause is more cautious because the risk of serious complications rises, but it isn't automatically "too late." The benefit-to-risk balance is most favorable when HRT is started before 60 or within 10 years of menopause, so later starts call for the lowest effective dose, often a non-oral route, and an individual risk review.
- Do I need progesterone if I still have a uterus?
- Usually yes, if you're taking systemic estrogen. Estrogen alone can overgrow the uterine lining and raise uterine (endometrial) cancer risk, so clinicians add a progestogen (progesterone or a progestin) to protect it — which is why the FDA kept the endometrial-cancer warning on estrogen-only systemic products.
- Can I use vaginal estrogen if I can't take systemic HRT?
- Often it's an option, because low-dose vaginal estrogen releases very little hormone into the bloodstream, and clinical guidelines treat it more gently than systemic HRT. But the product labels still list the systemic contraindications, so a red-flag history (breast cancer, clots, stroke, liver disease) needs a clinician's sign-off, and undiagnosed bleeding must be evaluated first.
- Did the FDA make HRT safe for everyone in 2025?
- No. The FDA began removing the broad boxed warning about cardiovascular disease, breast cancer, and dementia from estrogen products in November 2025, but that's a separate label section from the contraindications, which still stand. The change reduces outdated fear for appropriate candidates; it does not make HRT suitable for people with the red-flag conditions.
- What can I take instead of HRT?
- FDA-approved non-hormone medicines for menopausal hot flashes include Lynkuet (elinzanetant), Veozah (fezolinetant), and low-dose paroxetine (Brisdelle); other SSRIs/SNRIs, gabapentin, clonidine, and oxybutynin are used off-label. For vaginal dryness and painful sex, options include moisturizers and lubricants, low-dose vaginal estrogen, prasterone, and ospemifene. A clinician can match the option to your main symptom and history.
Still not sure which HRT program is right for you? Our quiz turns your answers into a personalized action plan — including, if you have a red flag, the clear advice to start with a specialist instead.
Take the free 60-second matching quiz →Sources
- ESTRADIOL tablet — Contraindications, DailyMed (U.S. National Library of Medicine). dailymed.nlm.nih.gov
- ESTRADIOL vaginal insert — Contraindications and systemic-absorption note, DailyMed. dailymed.nlm.nih.gov
- HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy — U.S. FDA (November 2025). fda.gov
- Hormone Replacement Therapy — StatPearls, NCBI Bookshelf. ncbi.nlm.nih.gov
- Menopause: identification and management (NG23) — NICE. nice.org.uk
- Treatment of Urogenital Symptoms in Individuals With a History of Estrogen-Dependent Breast Cancer — ACOG Clinical Consensus. acog.org
- Hormone Replacement Therapy (HRT) and risk of breast cancer — Cancer Australia. canceraustralia.gov.au
- HRT, family history, and breast cancer risk among postmenopausal women (WHI analysis) — PubMed. pubmed.ncbi.nlm.nih.gov
- Recurrent Ischemic Stroke and Vaginal Estradiol in Women With Prior Ischemic Stroke (Danish nested case-control, 2025) — Stroke, AHA. ahajournals.org
- FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) — U.S. FDA Drug Safety Communication. fda.gov
- LYNKUET (elinzanetant) — Prescribing Information, U.S. FDA / DailyMed. dailymed.nlm.nih.gov
- Is It Really ‘FDA Approved’? (compounded drugs are not FDA-approved) — U.S. FDA. fda.gov
- 13a. Controlled Substance Schedules (testosterone/anabolic steroids, Schedule III) — DEA Diversion Control Division. deadiversion.usdoj.gov